Met Life Investment Management, LLC Geron Corp Transaction History

Met Life Investment Management, LLC

$20.1 Billion
Q3 2025

A detailed history of Met Life Investment Management, LLC transactions in Geron Corp stock. As of the latest transaction made, Met Life Investment Management, LLC holds 266,749 shares of GERN stock, worth $298,758. This represents 0.0% of its overall portfolio holdings.

Number of Shares

266,749

Previous 363,137 26.54%

Holding current value

$298,758

Previous $512,000 28.71%

% of portfolio

0.0%

Previous 0.0%

74 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.1 - $1.47 $106,026 - $141,690	-96,388 Reduced 26.54%	266,749 $365,000
Q2 2025 Aug 13, 2025	BUY	$1.18 - $1.62 $68,238 - $93,682	57,829 Added 18.94%	363,137 $512,000
Q1 2025 May 14, 2025	SELL	$1.59 - $3.6 $67,751 - $153,399	-42,611 Reduced 12.25%	305,308 $485,000
Q4 2024 Feb 13, 2025	BUY	$3.3 - $4.44 $80,058 - $107,714	24,260 Added 7.5%	347,919 $1.23 Million
Q3 2024 Nov 13, 2024	SELL	$4.17 - $4.99 $37,959 - $45,423	-9,103 Reduced 2.74%	323,659 $1.47 Million

Q2 2024 Aug 13, 2024	BUY	$3.1 - $5.09 $189,682 - $311,446	61,188 Added 22.53%	332,762 $1.41 Million
Q1 2024 May 14, 2024	BUY	$1.75 - $3.44 $475,254 - $934,214	271,574 New	271,574 $896,000
Q3 2023 May 09, 2024	BUY	$2.11 - $3.28 $79,122 - $122,996	37,499 Added 16.65%	262,662 $556,000
Q2 2023 Apr 29, 2024	BUY	$1.97 - $3.69 $517,444 - $969,222	262,662 New	262,662 $843,000
Q2 2023 Aug 10, 2023	BUY	$1.97 - $3.69 $73,873 - $138,371	37,499 Added 16.65%	262,662 $843,000
Q1 2023 May 09, 2024	BUY	$2.14 - $3.4 $481,848 - $765,554	225,163 New	225,163 $489 Million
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $107,903 - $171,434	50,422 Added 28.86%	225,163 $488,000
Q4 2022 May 10, 2024	SELL	$2.03 - $2.42 $34,254 - $40,835	-16,874 Reduced 8.81%	174,741 $422,000
Q4 2022 Jun 14, 2023	SELL	$2.03 - $2.42 $102,356 - $122,021	-50,422 Reduced 22.39%	174,741 $422,000
Q4 2022 Mar 22, 2023	SELL	$2.03 - $2.42 $34,254 - $40,835	-16,874 Reduced 8.81%	174,741 $422,000
Q4 2022 Feb 15, 2023	SELL	$2.03 - $2.42 $34,254 - $40,835	-16,874 Reduced 8.81%	174,741 $422,000
Q3 2022 May 10, 2024	BUY	$1.67 - $2.94 $91,642 - $161,335	54,876 Added 40.13%	191,615 $448,000
Q3 2022 Jun 14, 2023	SELL	$1.67 - $2.94 $56,025 - $98,631	-33,548 Reduced 14.9%	191,615 $448,000
Q3 2022 Mar 22, 2023	BUY	$1.67 - $2.94 $91,642 - $161,335	54,876 Added 40.13%	191,615 $448,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $91,642 - $161,335	54,876 Added 40.13%	191,615 $448,000
Q2 2022 May 10, 2024	SELL	$1.19 - $1.65 $8,459 - $11,729	-7,109 Reduced 4.94%	136,739 $211,000
Q2 2022 Jun 20, 2023	SELL	$1.19 - $1.65 $105,224 - $145,899	-88,424 Reduced 39.27%	136,739 $211,000
Q2 2022 Mar 22, 2023	SELL	$1.19 - $1.65 $8,459 - $11,729	-7,109 Reduced 4.94%	136,739 $211,000
Q2 2022 Aug 11, 2022	SELL	$1.19 - $1.65 $8,459 - $11,729	-7,109 Reduced 4.94%	136,739 $212,000
Q1 2022 May 10, 2024	BUY	$0.99 - $1.6 $142,409 - $230,156	143,848 New	143,848 $195,000
Q1 2022 Jun 20, 2023	SELL	$0.99 - $1.6 $80,501 - $130,104	-81,315 Reduced 36.11%	143,848 $195,000
Q1 2022 Mar 22, 2023	BUY	$0.99 - $1.6 $28,402 - $45,902	28,689 Added 24.91%	143,848 $195,000
Q1 2022 May 12, 2022	BUY	$0.99 - $1.6 $28,402 - $45,902	28,689 Added 24.91%	143,848 $196,000
Q4 2021 May 17, 2024	BUY	$1.22 - $1.72 $63,908 - $90,100	52,384 Added 83.45%	115,159 $140,000
Q4 2021 Jun 21, 2023	SELL	$1.22 - $1.72 $134,204 - $189,206	-110,004 Reduced 48.86%	115,159 $140,000
Q4 2021 Mar 22, 2023	BUY	$1.22 - $1.72 $63,908 - $90,100	52,384 Added 83.45%	115,159 $140,000
Q4 2021 Feb 15, 2022	BUY	$1.22 - $1.72 $63,908 - $90,100	52,384 Added 83.45%	115,159 $140,000
Q3 2021 May 17, 2024	SELL	$1.2 - $1.5 $69,393 - $86,742	-57,828 Reduced 47.95%	62,775 $86,000
Q3 2021 Jun 21, 2023	SELL	$1.2 - $1.5 $194,865 - $243,582	-162,388 Reduced 72.12%	62,775 $86,000
Q3 2021 Mar 22, 2023	SELL	$1.2 - $1.5 $69,393 - $86,742	-57,828 Reduced 47.95%	62,775 $86,000
Q3 2021 Nov 15, 2021	SELL	$1.2 - $1.5 $69,393 - $86,742	-57,828 Reduced 47.95%	62,775 $86,000
Q2 2021 May 17, 2024	BUY	$1.25 - $1.83 $84,795 - $124,139	67,836 Added 128.56%	120,603 $170,000
Q2 2021 Jun 21, 2023	SELL	$1.25 - $1.83 $130,700 - $191,344	-104,560 Reduced 46.44%	120,603 $170,000
Q2 2021 Mar 22, 2023	BUY	$1.25 - $1.83 $84,795 - $124,139	67,836 Added 128.56%	120,603 $170,000
Q2 2021 Aug 16, 2021	BUY	$1.25 - $1.83 $84,795 - $124,139	67,836 Added 128.56%	120,603 $170,000
Q1 2021 May 17, 2024	SELL	$1.52 - $2.1 $332,586 - $459,494	-218,807 Reduced 80.57%	52,767 $83,000
Q1 2021 Jun 26, 2023	SELL	$1.52 - $2.1 $262,041 - $362,031	-172,396 Reduced 76.56%	52,767 $83.4 Million
Q1 2021 Mar 22, 2023	SELL	$1.52 - $2.1 $114,095 - $157,632	-75,063 Reduced 58.72%	52,767 $83,000
Q1 2021 May 14, 2021	SELL	$1.52 - $2.1 $114,095 - $157,632	-75,063 Reduced 58.72%	52,767 $83,000
Q4 2020 May 24, 2024	SELL	$1.55 - $2.05 $3,681 - $4,868	-2,375 Reduced 1.82%	127,830 $203,000
Q4 2020 Jun 22, 2023	SELL	$1.55 - $2.05 $150,866 - $199,532	-97,333 Reduced 43.23%	127,830 $203,000
Q4 2020 Mar 22, 2023	SELL	$1.55 - $2.05 $3,681 - $4,868	-2,375 Reduced 1.82%	127,830 $203,000
Q4 2020 Feb 16, 2021	SELL	$1.55 - $2.05 $3,681 - $4,868	-2,375 Reduced 1.82%	127,830 $203,000
Q3 2020 May 24, 2024	BUY	$1.59 - $2.19 $59,445 - $81,877	37,387 Added 40.28%	130,205 $227 Million
Q3 2020 Jun 26, 2023	SELL	$1.59 - $2.19 $150,983 - $207,958	-94,958 Reduced 42.17%	130,205 $226,000
Q3 2020 Mar 22, 2023	BUY	$1.59 - $2.19 $59,445 - $81,877	37,387 Added 40.28%	130,205 $226,000
Q3 2020 Nov 13, 2020	BUY	$1.59 - $2.19 $59,445 - $81,877	37,387 Added 40.28%	130,205 $227,000
Q2 2020 May 24, 2024	SELL	$1.05 - $2.18 $187,693 - $389,688	-178,756 Reduced 65.82%	92,818 $202 Million
Q2 2020 Jun 26, 2023	SELL	$1.05 - $2.18 $138,962 - $288,512	-132,345 Reduced 58.78%	92,818 $202,000
Q1 2020 Jul 12, 2023	SELL	$0.89 - $1.49 $117,787 - $197,194	-132,345 Reduced 58.78%	92,818 $110,000
Q1 2020 Mar 22, 2023	BUY	$0.89 - $1.49 $61,837 - $103,525	69,480 Added 297.71%	92,818 $110,000
Q1 2020 May 15, 2020	BUY	$0.89 - $1.49 $61,837 - $103,525	69,480 Added 297.71%	92,818 $110,000
Q4 2019 Jul 12, 2023	SELL	$1.27 - $1.54 $256,317 - $310,810	-201,825 Reduced 89.64%	23,338 $31,000
Q4 2019 Mar 22, 2023	SELL	$1.27 - $1.54 $87,538 - $106,149	-68,928 Reduced 74.71%	23,338 $31,000
Q4 2019 Feb 14, 2020	SELL	$1.27 - $1.54 $87,538 - $106,149	-68,928 Reduced 74.71%	23,338 $32,000
Q3 2019 Jul 12, 2023	SELL	$1.15 - $1.59 $152,831 - $211,306	-132,897 Reduced 59.02%	92,266 $122,000
Q3 2019 Mar 22, 2023	BUY	$1.15 - $1.59 $2,327 - $3,218	2,024 Added 2.24%	92,266 $122,000
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $2,327 - $3,218	2,024 Added 2.24%	92,266 $123,000
Q2 2019 Jul 12, 2023	SELL	$1.37 - $2.02 $184,841 - $272,540	-134,921 Reduced 59.92%	90,242 $127,000
Q1 2019 Jul 13, 2023	SELL	$1.01 - $1.83 $136,270 - $246,905	-134,921 Reduced 59.92%	90,242 $149,000
Q1 2019 Mar 22, 2023	SELL	$1.01 - $1.83 $27,195 - $49,274	-26,926 Reduced 22.98%	90,242 $149,000
Q1 2019 May 15, 2019	BUY	$1.01 - $1.83 $91,144 - $165,142	90,242 New	90,242 $150,000
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $114,824 - $216,760	-117,168 Closed	0 $0
Q3 2018 Jul 13, 2023	SELL	$1.76 - $6.38 $259,659 - $941,266	-147,534 Reduced 65.52%	77,629 $136,000
Q3 2018 Mar 22, 2023	SELL	$1.76 - $6.38 $101,328 - $367,315	-57,573 Reduced 32.95%	117,168 $206,000
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $68,807 - $249,426	39,095 Added 50.07%	117,168 $206,000
Q2 2018 Aug 15, 2018	BUY	$3.29 - $4.82 $107,819 - $157,961	32,772 Added 72.34%	78,073 $268,000
Q1 2018 May 15, 2018	SELL	$1.81 - $5.98 $54,819 - $181,116	-30,287 Reduced 40.07%	45,301 $193,000
Q4 2017 Feb 15, 2018	BUY	$1.8 - $2.32 $136,058 - $175,364	75,588	75,588 $136,000

Others Institutions Holding GERN

# of Institutions

288

Shares Held

502M

Call Options Held

643K

Put Options Held

276K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $423M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Geron Corp Transaction History